This is where MT-2 occupies its unique position
Wegovy (semaglutide) prescribing information, Food and Drug Administration (2024) Insulin resistance & prediabetes, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) (2025) Efficacy and safety of once-weekly semaglutide 2.4 mg versus placebo in people with obesity and prediabetes (STEP 10): A randomised, double-blind, placebo-controlled, multicentre phase 3 trial, The Lancet Diabetes & Endocrinology (2024) FDA approves first treatment to reduce risk of serious heart problems specifically in adults with obesity or overweight, Food and Drug Administration (2024) What is the list price for Wegovy and will it impact me?, NovoCare Details about the program, Centers for Disease Control and Prevention (2024) Medicare Diabetes Prevention Program, Centers for Medicare and Medicaid Services Medically accurate: SingleCares Medical Review Board analyzes all of our content to confirm its in line with current medical advice

Acquisition Mode: MRM (Multiple Reaction Monitoring) for high specificity and precision
Rising prevalence of diabetes and obesity, advancement in drug delivery technologies, and growing focus on preventive healthcare and personalized medicine are major key factors driving the market revenue growth of the GLP-1 Receptor Agonist market